About
Nanomedicine
Areas of Focus
Categories
NanotechVaccineSmall Molecule Pharmaceutical
Team (10)
Ann Merchant
Non-executive Director
Biodexa Pharmaceuticals
team_member
Dan Palmer
VP Technology
Biodexa Pharmaceuticals
executive
Fiona Sharp
Group Financial Controller
Biodexa Pharmaceuticals
team_member
Gary Shangold
Chief Medical Officer
Biodexa Pharmaceuticals
executive
Noreen Bhatti
Vice President of Clinical Operations
Biodexa Pharmaceuticals
executive
Sijmen de Vries
Non-executive Director
Biodexa Pharmaceuticals
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
202
By Phase
PHASE3: 1PHASE1: 1PHASE2: 1
By Status
RECRUITING: 1TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06950385Collaborator
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
PHASE3Recruiting
168 participants
Started: Jul 18, 2025 · Completed: Jan 31, 2031
NCT05324501Lead Sponsor
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
PHASE1Terminated
4 participants
Started: Oct 19, 2022 · Completed: Sep 10, 2024
NCT04230499Collaborator
Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
PHASE2Active, not recruiting
30 participants
Started: Jan 18, 2021 · Completed: Mar 31, 2025
Locations (1)
Headquarters
Cardiff, UK
Map
Loading map...